论文部分内容阅读
目的探讨血管介入治疗肺癌的疗效。方法 2012年12月至2014年3月间治疗的106例原发性肺癌患者进行血管介入治疗(介入组),并与同期90例行吉西他滨联合顺铂(GP)方案进行全身化疗的患者(GP组)进行比较,评价治疗后效果。结果介入组患者和完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)及疾病进展(PD)均明显优于GP组,介入组和GP组的总有效率分别为80.2%和48.9%,介入组患者的不良反应发生率明显低于GP组。结论血管介入治疗在治疗肺癌中的应用具有很好的前景,可作为临床治疗肺癌的有效手段。
Objective To investigate the therapeutic effect of vascular intervention on lung cancer. Methods 106 patients with primary lung cancer treated between December 2012 and March 2014 were enrolled in the interventional treatment group (intervention group), and compared with 90 patients treated with gemcitabine plus cisplatin (GP) for systemic chemotherapy Group) were compared to evaluate the effect after treatment. Results The total effective rate (CR), partial remission (PR), stable disease (SD) and disease progression (PD) in the intervention group were significantly better than those in the GP group. The total effective rate was 80.2% in the intervention group and 48.9% in the GP group %, The incidence of adverse reactions in intervention group was significantly lower than that in GP group. Conclusion The application of vascular intervention in the treatment of lung cancer has a good prospect, which can be used as an effective clinical treatment of lung cancer.